{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:16:41Z","timestamp":1783124201683,"version":"3.54.6"},"reference-count":36,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"DOI":"10.1590\/1806-9282.66.s1.17","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T19:48:48Z","timestamp":1578944928000},"page":"s17-s24","source":"Crossref","is-referenced-by-count":22,"title":["SGLT-2 inhibitors in diabetes: a focus on renoprotection"],"prefix":"10.1590","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-9158","authenticated-orcid":false,"given":"Diego Ennes","family":"Gonzalez","sequence":"first","affiliation":[{"name":"Hospital do Rim,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-0265","authenticated-orcid":false,"given":"Renato Demarchi","family":"Foresto","sequence":"additional","affiliation":[{"name":"Hospital do Rim,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8624-5302","authenticated-orcid":false,"given":"Artur Beltrame","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Hospital do Rim,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2020]]},"reference":[{"key":"ref1","series-title":"Global report on diabetes","year":"2016"},{"issue":"9887","key":"ref2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","article-title":"Evolving importance of kidney disease: from subspecialty to global health burden","volume":"382","author":"Eckardt KU","year":"2013","journal-title":"Lancet"},{"issue":"13","key":"ref3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go AS","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian M","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5935\/0101-2800.20170049","article-title":"Brazilian Chronic Dialysis Survey 2016","volume":"39","author":"Sesso RC","year":"2017","journal-title":"Braz J Nephrol"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome","volume":"12","author":"van Bommel EJ","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright EM","year":"2011","journal-title":"Physiol Rev"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani MA","year":"2011","journal-title":"Endocr Rev"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo RA","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on diabetic nephropathy: core curriculum 2018","volume":"71","author":"Umanath K","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","article-title":"CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease","volume":"14","author":"Anders HJ","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck L","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti L","year":"1987","journal-title":"J Clin Invest"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucosereabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo RA","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney DZ","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink HJ","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107 M","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill J","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima A","year":"2015","journal-title":"Horm Metab Res"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock J","year":"2014","journal-title":"Diabetes Care"},{"issue":"22","key":"ref21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"ref24","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang HY","year":"2018","journal-title":"JAMA Intern Med"},{"key":"ref27","series-title":"A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD)"},{"key":"ref28","series-title":"A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger E","year":"2019","journal-title":"Am J Transplant"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa BC","year":"2018","journal-title":"Diabetologia"},{"key":"ref31","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","author":"Dave CV","year":"2019","journal-title":"Ann Intern Med"},{"issue":"9131","key":"ref32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet MHA","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"s90","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock C","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2019.05.009","article-title":"Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors","author":"Bakris GL","year":"2019","journal-title":"Am J Kidney Dis"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v66s1\/1806-9282-ramb-66-s1-s17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T04:16:20Z","timestamp":1611375380000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302020001300017&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":36,"journal-issue":{"issue":"suppl 1","published-online":{"date-parts":[[2020]]}},"alternative-id":["S0104-42302020001300017"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.66.s1.17","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}